Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Intra-Cellular Therapies (ITCI) Insider Trading & Ownership

Intra-Cellular Therapies logo

Intra-Cellular Therapies (NASDAQ:ITCI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
2.60%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
2
Amount Of
Insider Selling
(Last 12 Months)
$6.41M
Get ITCI Insider Trade Alerts

Want to know when executives and insiders are buying or selling Intra-Cellular Therapies stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITCI Insider Buying and Selling by Quarter

Intra-Cellular Therapies Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$131.87$1,001 - $15,000
4/3/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Sell$131.87$1,001 - $15,000
3/24/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Sell$131.70$1,001 - $15,000
3/17/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$131.45$1,001 - $15,000
1/24/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$127.35$1,001 - $15,000
12/4/2024Sharon MatesCEOSell51,000$85.80$4,375,800.00  
11/12/2024Michael HalsteadPresidentSell22,869$89.12$2,038,085.28  
(Data available from 1/1/2013 forward)

ITCI Insider Trading Activity - Frequently Asked Questions

The list of insiders at Intra-Cellular Therapies includes Joel S Marcus, Lawrence J. Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam. Learn more on insiders at ITCI.

2.60% of Intra-Cellular Therapies stock is owned by insiders. Learn more on ITCI's insider holdings.

The following insiders have sold ITCI shares in the last 24 months: Joel S Marcus ($1,808,207.04), Lawrence J. Hineline ($2,468,160.27), Mark Neumann ($3,763,369.71), Michael Halstead ($6,413,908.64), Nostrand Robert L Van ($1,518,200.00), Rory B Riggs ($337,193.34), Sharon Mates ($34,116,938.78), and Suresh K Durgam ($429,312.00).

Insiders have sold a total of 816,936 Intra-Cellular Therapies shares in the last 24 months for a total of $56,634,428.98 sold.

Josh Gottheimer (D-NJ) and Gilbert Ray Cisneros, Jr. (D-CA) have sold shares of Intra-Cellular Therapies in the last year totaling $40,000.

Intra-Cellular Therapies Key Executives

  • Dr. Sharon Mates Ph.D. (Age 71)
    Co-Founder, Chairman & CEO
    Compensation: $2.23M
  • Mr. Michael I. Halstead J.D. (Age 51)
    President
    Compensation: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Compensation: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 61)
    EVP & Chief Commercial Officer
    Compensation: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 73)
    Senior VP & Chief Scientific Officer
    Compensation: $646.12k
  • Mr. Juan Fernando Sanchez (Age 53)
    Vice President of Corporate Communications & Investor Relations
    Compensation: $296.75k
  • Ms. Karen Patruno Sheehy Esq. (Age 62)
    Senior VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Senior VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Senior VP of Market Access, Policy & Government Affairs
  • Dr. Willie R. Earley M.D.
    Senior VP & Head of Clinical Development


This page (NASDAQ:ITCI) was last updated on 9/9/2025 by MarketBeat.com Staff
From Our Partners